Please assess the completion status of the following clinical trial:

Trial Title: Study of Everolimus in de Novo Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant patients~* Age between 18 and 85 years~* Recipients of living or deceased donors~* Donor under the age of 85 years~* Panel Reactivity Antibodies (PRA) over or equal to 30%~* 4-5 months post-transplant~* CNI-based immunosuppressive regimen~* Stable graft function (creatinine lower than 2.0 mg/dl)~* No currently acute rejection~* Proteinuria lower than 800mg/d~* No laboratory or physical clinically significant signs presented for the last 2 months before screening.~Exclusion Criteria:~* Recipient of multiple organs~* Recipient with a history of focal segmental glomerulosclerosis or membranous glomerulonephritis~* Presence of uncontrolled hypercholesterolemia (≥350 mg/dL)hypertriglyceridemia (over or equal to 500 mg/dL)~* Patients with eGFR lower than 40 ml/min/1.73m2~* Evidence of acute rejection within 2 months before screening~* Thrombocytopenia (lower than 75,000/mm3)~* Neutropenia (lower than 1,500/mm3)~* Leukocytopenia (lower than 2500/mm3)~* Anemia (hemoglobin lower than 6.0g/dL)~* Severe liver disease (including transaminases or bilirubin equal or over 3 times normal)~* Proteinuria over 800mg/dL~* Systemic infection or pneumonia (active infection)~* Positive for Hepatitis B, Hepatitis C or HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): 35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day
- Intervention (Type: ACTIVE_COMPARATOR): 35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.

Based on this trial design, predict the completion outcome and termination type (if applicable).